Dresden, July 5, 2024 - DEMECAN is pleased to announce that it has become the first German company to receive a cultivation license for medical cannabis under the new Medical Cannabis Law (MedCanG). This license includes several different phenotypes that DEMECAN will now cultivate for the German market. With this license, DEMECAN can immediately double its production and fully utilize the existing production capacities at the "Cannabis Campus" in Ebersbach. This license allows DEMECAN to achieve an annual yield of approximately 2 tons, with no quantity limit specified.
This license is crucial to meet the growing demand for medical cannabis and marks a
turning point in supply by shifting the focus from imports to more domestic production.
Dr. Adrian Fischer, physician and Managing Director responsible for cultivation,
commented: "This license is a huge step forward for DEMECAN and the entire
industry. We are proud to be the first German company to take this step and look
forward to providing our high-quality cannabis strains soon. Our goal is to further
increase production and thus improve supply security, as there are currently many
shortages in patient care."
The company is also pleased to announce that it achieved strong revenue growth since
April 2024. Dr. Philipp Goebel, Managing Director and responsible for sales, adds:
"The significantly increased demand is reflected in our strong sales and shows that we
are on the right track. The new cultivation permit not only allows us to meet the growing
demand but also enables the sustainable development of our company."
Since its founding in 2017, DEMECAN has established itself as a pioneer in the
German cannabis scene. As the only independent company in Germany covering the
entire value chain for medical cannabis - from cultivation and processing to storage
and delivery to pharmacies - DEMECAN has made a significant contribution to
ensuring patients are supplied with high-quality cannabis products.
The legalization of cannabis on April 1, 2024, has also significantly boosted the market
for medical cannabis, and DEMECAN's new cultivation license sends another positive
signal for the industry. With the expansion of production in Germany, DEMECAN aims
to offer consumers quality-tested products from strictly regulated production.
About DEMECAN
DEMECAN is an independent German company covering the entire value chain of
medical cannabis - from cultivation and pharmaceutical manufacturing to delivery to
pharmacies. The company was founded with the goal of providing patients with highquality access to medical cannabis "Made in Germany."
As the only independent German company, DEMECAN received the contract from the
Federal Institute for Drugs and Medical Devices (BfArM) in May 2019 to grow medical
cannabis in Germany. Cultivation and further processing are carried out according to
the highest pharmaceutical standards at the facility near Dresden. Additionally,
DEMECAN imports medical cannabis from producers worldwide to expand its range
and meet high-quality standards. The company also offers laboratory and processing
services related to medical cannabis.
DEMECAN is a member of the Federal Association of Pharmaceutical Cannabinoid
Companies (BPC) and the Federal Association of the Cannabis Industry (BvCW). With
its commitment to the highest quality and safety in medical cannabis production,
DEMECAN contributes to improving patient care in Germany and Europe.
For more information: www.demecan.de
Press Contact: Franz Großmann
Mail: press@demecan.de
Mobil: +49 151 742 25 332
